Epilepsy Drugs Market Insights: Market Size, Unmet Needs & Future Opportunities According to a newly published market research report by 24LifeSciences, global epilepsy drugs market was valued at USD 4614 million in 2024 and is projected to reach USD 5695 million by 2031, growing at a compound annual growth rate (CAGR) of 3.1% during the forecast period 2024–2031. Anti-epileptic drugs (AEDs), also known as anticonvulsants, are a critical class of pharmaceuticals designed to control and manage epileptic seizures by stabilizing the electrical activity in the brain. The therapeutic landscape is broadly categorized into First Generation agents, including drugs like valproate and carbamazepine, and the newer Second Generation drugs, such as levetiracetam and lamotrigine, which offer improved safety profiles. These medications function through mechanisms that either enhance inhibitory neurotransmission, primarily via GABA, or reduce excitatory signals, providing essential seizure control for millions of patients globally. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/8874/epilepsy-drugs-market